Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry

It looks like Eli Lil­ly and Te­va Phar­ma­ceu­ti­cals are go­ing to tri­al.

A fed­er­al ap­peals court on Mon­day re­fused to in­val­i­date three of Te­va’s patents for its mi­graine treat­ment Ajovy, while al­so de­clin­ing to is­sue a sum­ma­ry judg­ment in fa­vor of ei­ther com­pa­ny, which would ef­fec­tive­ly end the case with­out a full tri­al.

Te­va filed suit against Lil­ly back in 2018, al­leg­ing that the com­pa­ny in­fringed up­on nine patents with its ri­val mi­graine drug Em­gal­i­ty. The ri­val drugs were both ap­proved in Sep­tem­ber 2018 for the pre­ven­ta­tive treat­ment of mi­graine, and are de­signed to block cal­ci­tonin gene-re­lat­ed pep­tide (CGRP), a pro­tein as­so­ci­at­ed with the on­set of mi­graine pain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.